Randomized trial · people

Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large placebo-controlled trial, weekly semaglutide improved liver biopsy results in people with MASH and moderate or advanced scarring, with more gut side effects than placebo.

Kind
Randomized trial
Studied in
People
Number studied
1197
Published
2025
Journal
N Engl J Med

What they tested

Could once-weekly semaglutide improve the liver in people with MASH and moderate or advanced liver scarring?

How the study was done

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial in 1197 patients with biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation) and fibrosis (scarring) stage 2 or 3. Patients got weekly semaglutide 2.4 mg shots or placebo (a dummy shot) in a 2:1 ratio over a planned 240 weeks, and this planned interim analysis covers the first 800 patients at week 72.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Steatohepatitis cleared up without fibrosis getting worse in 62.9% of the 534 patients on semaglutide and 34.3% of the 266 on placebo, an estimated difference of 28.7 percentage points. Fibrosis improved without steatohepatitis getting worse in 36.8% on semaglutide and 22.4% on placebo. Both happened together in 32.7% and 16.1%, and body weight changed by -10.5% with semaglutide and -2.0% with placebo. Bodily pain scores did not differ significantly between groups, and gut-related side effects were more common with semaglutide.

What it doesn’t show

These are 72-week interim results from the first 800 patients in a trial still running toward 240 weeks, so longer-term outcomes are not yet known. The trial was funded by Novo Nordisk.

The paper

Sanyal et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo